MAIA Biotechnology Inc (MAIA)
3.28
+0.13
(+4.13%)
USD |
NYAM |
May 03, 16:00
3.22
-0.06
(-1.83%)
After-Hours: 20:00
MAIA Biotechnology Enterprise Value: 60.36M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 60.36M |
| May 02, 2024 | 57.68M |
| May 01, 2024 | 52.95M |
| April 30, 2024 | 53.15M |
| April 29, 2024 | 58.92M |
| April 26, 2024 | 53.36M |
| April 25, 2024 | 48.01M |
| April 24, 2024 | 48.21M |
| April 23, 2024 | 43.48M |
| April 22, 2024 | 39.36M |
| April 19, 2024 | 37.10M |
| April 18, 2024 | 33.19M |
| April 17, 2024 | 33.60M |
| April 16, 2024 | 35.25M |
| April 15, 2024 | 34.84M |
| April 12, 2024 | 38.23M |
| April 11, 2024 | 42.86M |
| April 10, 2024 | 43.48M |
| April 09, 2024 | 45.74M |
| April 08, 2024 | 44.10M |
| April 05, 2024 | 41.22M |
| April 04, 2024 | 38.13M |
| April 03, 2024 | 40.60M |
| April 02, 2024 | 41.22M |
| April 01, 2024 | 43.89M |
| Date | Value |
|---|---|
| March 28, 2024 | 38.13M |
| March 27, 2024 | 42.46M |
| March 26, 2024 | 41.66M |
| March 25, 2024 | 43.86M |
| March 22, 2024 | 35.06M |
| March 21, 2024 | 31.65M |
| March 20, 2024 | 25.00M |
| March 19, 2024 | 25.77M |
| March 18, 2024 | 22.07M |
| March 15, 2024 | 19.93M |
| March 14, 2024 | 18.37M |
| March 13, 2024 | 15.61M |
| March 12, 2024 | 15.10M |
| March 11, 2024 | 14.90M |
| March 08, 2024 | 15.44M |
| March 07, 2024 | 16.63M |
| March 06, 2024 | 17.82M |
| March 05, 2024 | 17.99M |
| March 04, 2024 | 17.48M |
| March 01, 2024 | 16.55M |
| February 29, 2024 | 15.10M |
| February 28, 2024 | 16.29M |
| February 27, 2024 | 15.95M |
| February 26, 2024 | 16.12M |
| February 23, 2024 | 16.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.975M
Minimum
Dec 12 2023
75.94M
Maximum
Aug 01 2022
25.89M
Average
24.16M
Median
Jun 16 2023
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.7414M |
| Avid Bioservices Inc | 634.42M |
| Oragenics Inc | 3.216M |
| NeuBase Therapeutics Inc | -11.06M |
| Viking Therapeutics Inc | 7.524B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.257M |
| Total Expenses (Quarterly) | 6.351M |
| EPS Diluted (Quarterly) | -0.41 |
| Earnings Yield | -45.73% |